Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
169.12M | 27.96M | 0.00 | 0.00 | 22.33M | Gross Profit |
153.84M | 27.12M | -1.49M | -815.00K | 16.59M | EBIT |
-42.40M | -137.85M | -98.56M | -85.55M | -36.66M | EBITDA |
-35.57M | -149.13M | -97.60M | -84.78M | -34.97M | Net Income Common Stockholders |
-48.83M | -160.28M | -137.46M | -77.33M | 7.03M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
73.78M | 105.11M | 96.50M | 157.22M | 221.40M | Total Assets |
164.24M | 164.70M | 132.78M | 247.26M | 311.64M | Total Debt |
1.70M | 35.38M | 131.02M | 145.00M | 130.52M | Net Debt |
-49.67M | 4.22M | 57.04M | 94.30M | 58.80M | Total Liabilities |
90.39M | 76.96M | 153.93M | 169.02M | 149.37M | Stockholders Equity |
73.85M | 87.74M | -21.14M | 78.24M | 162.27M |
Cash Flow | Free Cash Flow | |||
-46.91M | -128.51M | -71.02M | -77.34M | -48.83M | Operating Cash Flow |
-46.91M | -128.51M | -70.30M | -77.31M | -48.73M | Investing Cash Flow |
51.78M | -50.09M | 79.70M | 56.93M | -69.72M | Financing Cash Flow |
15.97M | 135.34M | 14.54M | 263.00K | 179.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $860.81M | 14.50 | 32.62% | ― | 11.41% | 45.89% | |
58 Neutral | $172.66M | ― | -72.60% | ― | -29.11% | -219.44% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
51 Neutral | $298.31M | ― | -33.67% | ― | -0.62% | 75.57% | |
47 Neutral | $847.44M | ― | -60.44% | ― | 504.79% | 74.24% | |
42 Neutral | $182.30M | ― | 23.44% | ― | 185.66% | 89.22% | |
40 Underperform | $283.76M | ― | 77.48% | ― | 13.80% | -389.41% |
On April 8, 2025, Avadel Pharmaceuticals provided an update at the Needham Virtual Healthcare Conference, highlighting improved patient demand metrics for their narcolepsy medication, LUMRYZ, in Q1 2025 compared to Q4 2024. The company is on track with its REVITALYZ Phase 3 trial and has initiated patent infringement lawsuits against Jazz Pharmaceuticals. Avadel expects sustainable positive cash flow in 2025 and has strengthened its supply chain to mitigate potential impacts from U.S. tariff policy changes.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals shows promising revenue growth and optimistic future guidance, particularly from LUMRYZ, which boosts its earnings call score. However, financial performance and technical analysis indicate ongoing challenges with profitability, cash flow, and bearish stock momentum, which significantly impact the overall score.
To see Spark’s full report on AVDL stock, click here.